Blockade of CD300A enhances the ability of human NK cells to lyse hematologic malignancies

Objective: The human cluster of differentiation(CD)300A, a type-I transmembrane protein with immunoreceptor tyrosine-based inhibitory motifs, was investigated as a potential immune checkpoint for human natural killer(NK) cells targeting hematologic malignancies(HMs).Methods: We implemented a stimulation system involving the CD300A ligand, phosphatidylserine(PS), exposed to the outer surface of malignant cells. Additionally, we utilized CD300A overexpression, a CD300A blocking system, and a xenotransplantation model to evaluate the impact of CD300A on NK cell efficacy against HMs in in vitro and in vivo settings. Furthermore, we explored the association between CD300A and HM progression in patients.Results: Our findings indicated that PS hampers the function of NK cells. Increased CD300A expression inhibited HM lysis by NK cells. CD300A overexpression shortened the survival of HM-xenografted mice by impairing transplanted NK cells. Blocking PS–CD300A signals with antibodies significantly amplified the expression of lysis function-related proteins and effector cytokines in NK cells, thereby augmenting the ability to lyse HMs. Clinically, heightened CD300A expression correlated with shorter survival and an “exhausted” phenotype of intratumoral NK cells in patients with HMs or solid tumors.Conclusions: These results propose CD300A as a potential target for invigorating NK cell-based treatments against HMs.

Long Non-coding RNA PCED1B Antisense RNA 1 Promotes Cell Proliferation and Invasion in Hepatocellular Carcinoma by Regulating the MicroRNA-34a/CD44 Axis

Objective This study aimed to examine the role of long non-coding RNA PCED1B antisense RNA 1(PCED1B-AS1)in the development of hepatocellular carcinoma(HCC).Methods A total of 62 pairs of HCC tissues and adjacent non-tumor tissues were obtained from 62 HCC patients.The interactions of PCED1B-AS1 and microRNA-34a(miR-34a)were detected by dual luciferase activity assay and RNA pull-down assay.The RNA expression levels of PCED1B-AS1,miR-34a and CD44 were detected by RT-qPCR,and the protein expression level of CD44 was determined by Western blotting.The cell proliferation was detected by cell proliferation assay,and the cell invasion and migration by transwell invasion assay.The HCC tumor growth after PCED1B-AS1 was downregulated was determined by in vivo animal study.Results PCED1B-AS1 was highly expressed in HCC tissues,which was associated with poor survival of HCC patients.Furthermore,PCED1B-AS1 interacted with miR-34a in HCC cells,but they did not regulate the expression of each other.Additionally,PCED1B-AS1 increased the expression level of CD44,which was targeted by miR-34a.The cell proliferation and invasion assay revealed that miR-34a inhibited the proliferation and invasion of HCC in vitro,while CD44 exhibited the opposite effects.Furthermore,PCED1B-AS1 suppressed the role of miR-34a.Moreover,the knockdown of PCED1B-AS1 repressed the HCC tumor growth in nude mice in vivo.Conclusion PCED1B-AS1 may play an oncogenic role by regulating the miR-34a/CD44 axis in HCC.

Identification of prognostic molecular subtypes and model based on CD8+ T cells for lung adenocarcinoma

Background:Cytotoxic T lymphocytes(CD8+T)cells function critically in mediating anti-tumor immune response in cancer patients.Characterizing the specific functions of CD8+T cells in lung adenocarcinoma(LUAD)could help better understand local anti-tumor immune responses and estimate the effect of immunotherapy.Methods:Gens related to CD8+T cells were identified by cluster analysis based on the single-cell sequencing data of three LUAD tissues and their paired normal tissues.Weighted gene co-expression network analysis(WGCNA),consensus clustering,differential expression analysis,least absolute shrinkage and selection operator(LASSO)and Cox regression analysis were conducted to classify molecular subtypes for LUAD and to develop a risk model using prognostic genes related to CD8+T cells.Expression of the genes in the prognostic model,their effects on tumor cell invasion,and interactions with CD8+T cells were verified by cell experiments.Results:This study defined two LUAD clusters(CD8+0 and CD8+1)based on CD8+T cells,with cluster CD8+0 being significantly associated with the prognosis of LUAD.Three heterogeneous subtypes(clusters 1,2,and 3)differing in prognosis,genome mutation events,and immune status were categorized using 42 prognostic genes.A prognostic model created based on 11 significant genes(including CD200R1,CLEC17A,ZC3H12D,GNG7,SNX30,CDCP1,NEIL3,IGF2BP1,RHOV,ABCC2,and KRT81)was able to independently estimate the death risk for patients in different LUAD cohorts.Moreover,the model also showed general applicability in external validation cohorts.Low-risk patients could benefit more from taking immunotherapy and were significantly related to the resistance to anticancer drugs.The results from cell experiments demonstrated that the expression of CD200R1,CLEC17A,ZC3H12D,GNG7,and SNX30 was significantly downregulated,while that of CDCP1,NEIL3,IGF2BP1,RHOV,ABCC2 and KRT81 was upregulated in LUAD cells.Inhibition of CD200R1 greatly increased the invasiveness of the LUAD cells,but inhibiting CDCP1 expression weakened the invasion ability of LUAD cells.Conclusion:This study defined two prognostic CD8+T cell clusters and classified three heterogeneous molecular subtypes for LUAD.A prognostic model predictive of the potential effects of immunotherapy on LUAD patients was developed.

Repetitive administration of cultured human CD34+cells improve adenine-induced kidney injury in mice

BACKGROUND There is no established treatment to impede the progression or restore kidney function in human chronic kidney disease(CKD).AIM To examine the efficacy of cultured human CD34+cells with enhanced proliferating potential in kidney injury in mice.METHODS Human umbilical cord blood(UCB)-derived CD34+cells were incubated for one week in vasculogenic conditioning medium.Vasculogenic culture significantly increased the number of CD34+cells and their ability to form endothelial progenitor cell colony-forming units.Adenineinduced tubulointerstitial injury of the kidney was induced in immunodeficient non-obese diabetic/severe combined immunodeficiency mice,and cultured human UCB-CD34+cells were administered at a dose of 1×106/mouse on days 7,14,and 21 after the start of adenine diet.RESULTS Repetitive administration of cultured UCB-CD34+cells significantly improved the time-course of kidney dysfunction in the cell therapy group compared with that in the control group.Both interstitial fibrosis and tubular damage were significantly reduced in the cell therapy group compared with those in the control group(P<0.01).Microvasculature integrity was significantly preserved(P<0.01)and macrophage infiltration into kidney tissue was dramatically decreased in the cell therapy group compared with those in the control group(P<0.001).CONCLUSION Early intervention using human cultured CD34+cells significantly improved the progression of tubulointerstitial kidney injury.Repetitive administration of cultured human UCB-CD34+cells significantly improved tubulointerstitial damage in adenine-induced kidney injury in mice via vasculoprotective and anti-inflammatory effects.

超声引导下粗针活检术联合CD34免疫组化标记在隆突性皮肤纤维肉瘤诊断中的应用

目的探讨超声引导下粗针活检术联合CD34在隆突性皮肤纤维肉瘤的诊断中的应用价值。方法回顾性分析于术前经超声引导下粗针活检术及CD34免疫组化标记诊断为隆突性皮肤纤维肉瘤的32例患者的病理资料与超声检查结果,并将其与手术后病理结果进行对比分析。结果32例患者中,30例患者于术前经超声引导下粗针活检术及CD34免疫组化标记诊断为隆突性皮肤纤维肉瘤,1例患者诊断为“倾向于隆突性皮肤纤维肉瘤”,另1例考虑“间叶源性肿瘤,不能除外纤维肉瘤”。术后病理结果提示31例患者为隆突性皮肤纤维肉瘤,1例患者为纤维肉瘤型皮肤纤维肉瘤。超声引导下粗针活检术联合CD34免疫组化标记诊断隆突性皮肤纤维肉瘤与术后病理结果的符合率为93.75%(30/31)。结论超声引导下粗针活检术联合CD34免疫组化标记诊断隆突性皮肤纤维肉瘤的准确性高,具有较大的临床应用价值。

CD34^(+)细胞数对单倍体造血干细胞移植治疗恶性血液病的影响

背景:单倍体造血干细胞移植与较高的植入功能不良相关,因此经常要求更高的CD34^(+)细胞数量,但现有研究关于异基因造血干细胞移植CD34+细胞剂量和研究终点关系的结论是有争议的。目的:探究CD34^(+)细胞数对单倍体造血干细胞移植治疗恶性血液疾病临床结果的影响。方法:纳入2019年1月至2021年12月期间于郑州大学第一附属医院造血干细胞移植中心行单倍体造血干细胞移植的恶性血液病患者,总计135例。结合既往研究结果及移植中心经验,以CD34+细胞数5.0×10^(6)/kg为截止点,将队列分为2组。评估两组的移植物植入情况、复发率及非复发死亡率、总生存期和无进展生存期等相关临床指标。结果与结论:①CD34+细胞剂量与血小板的植入相关,高剂量组血小板的植入时间早于低剂量组(14 d vs.16 d,P=0.013)。②两组患者3年总生存期无显著差异(67.5%vs.53.8%,P=0.257);两组间的无进展生存期也无显著性差异(65.6%vs.44.2%,P=0.106),但根据疾病风险指数(DRI)进行分层分析后发现低危患者高剂量组的3年无进展生存期较低剂量组升高(72.0%vs.49.3%,P=0.036)。③高剂量组3年累积复发率小于低剂量组(16.0%vs.33.5%,P=0.05)。④两组100 d内非复发死亡率高剂量组大于低剂量组,但无显著差异(17.3%vs.6.7%,P=0.070);进行分层分析发现,高危患者中高剂量组100 d内非复发死亡率明显高于低剂量组(20.0%vs.3.3%,P=0.046)。⑤综上所述,输注>5.0×10^(6)/kg的CD34^(+)细胞可促进血小板早期植入,可改善移植中低危风险患者的3年无进展生存期,并且降低移植后累积复发率;但在高危患者中,高剂量CD34+细胞导致移植后100 d内的非复发死亡率增高,考虑可能与移植后早期重度急性移植物抗宿主病的发生增多相关,因此考虑对回输高剂量CD34+细胞的患者应加强移植物抗宿主病的监测。

外周血CD4^(+)PD-1^(+)Tcells及CD4^(+)T淋巴细胞ATP含量与复发性卵巢癌疗效的相关性分析

目的 探讨外周血CD4^(+)程序性细胞死亡受体-1(PD-1)^(+)T cells及CD4^(+)T淋巴细胞三磷酸腺苷(ATP)含量与复发性卵巢癌疗效的相关性。方法 选取30例复发性卵巢癌患者为复发组,30例未复发卵巢癌患者为非复发组;另选取30名同期体检健康者作为对照组。评估外周血CD4^(+)PD-1^(+)T cells及CD4^(+)T淋巴细胞ATP含量与复发性卵巢癌疗效的相关性。结果 复发组和非复发组的CD4^(+)PD-1^(+)T cells较对照组明显升高(P<0.05)。复发组和非复发组的CD4^(+)T淋巴细胞ATP含量较对照组明显降低(P<0.05)。复发组治疗后CD4^(+)PD-1^(+)Tcells显著低于治疗前(P<0.05),治疗后CD4^(+)T淋巴细胞ATP含量显著高于治疗前(P<0.05)。CD4^(+)PD-1^(+)T cells与复发性卵巢癌疗效成负相关(r=-0.393,P=0.039),CD4^(+)T淋巴细胞ATP含量与复发性卵巢癌疗效成正相关(r=0.449,P=0.031)。结论 复发性卵巢癌患者外周血CD4^(+)PD-1^(+)T cells及CD4^(+)T淋巴细胞ATP含量与疗效密切相关。

浅表性CD34阳性纤维母细胞肿瘤6例临床病理分析及文献复习

目的探讨浅表性CD34阳性纤维母细胞肿瘤(superficial CD34 positive fibroblastic tumors,SCPFT)的临床病理特点、免疫表型、诊断和鉴别诊断。方法回顾性分析6例SCPFT,行常规HE染色、免疫组化EliVision法染色。应用FISH法检测PRDM10基因断裂情况,并复习相关文献资料。结果6例SCPFT患者中,男性2例、女性4例。其中4例肿块位于下肢皮下,1例位于下腹部,另1例位于外阴。镜检:肿瘤细胞排列呈束状、实片状,细胞核明显多形性或畸形,核仁明显,可见核内假包涵体,胞质嗜酸性,部分区域细胞呈上皮样,未见核分裂象,间质散在少量炎细胞,免疫表型:肿瘤细胞弥漫强表达CD34和INI1,部分细胞表达CK(AE1/AE3),不表达SMA、CD68、desmin、S-100、CD31和ERG,Ki67增殖指数低于3%。FISH检测:4例SCPFT行FISH检测,其中3例PRDM10呈阳性。结论SCPFT是新近报道的一种软组织肿瘤,具有交界性或低度恶性生物学行为,诊断需与多种CD34阳性的软组织肿瘤相鉴别,避免过度诊断及治疗。

Bcl-2与CD34在基底细胞癌和毛发上皮瘤中的表达及意义

目的:探讨B淋巴细胞瘤-2基因(Bcl-2)和集落分化抗原34(CD34)在基底细胞癌和毛发上皮瘤中的表达及意义。方法:选取2008年1月—2023年9月常熟市第五人民医院收治的基底细胞癌和毛发上皮瘤143例,根据不同疾病类型将患者分成毛发上皮瘤组(n=85)和基底细胞癌组(n=58),对所有患者进行免疫组化检查,比较Bcl-2与CD34在不同疾病中的表达。结果:基底细胞癌组Bcl-2表达的阳性率为100.00%,CD34表达的阳性率为0.00%,毛发上皮瘤组Bcl-2表达的阳性率为89.41%,CD34表达的阳性率为13.48%,两组Bcl-2表达阳性率比较,差异有统计学意义(P<0.05)。Bcl-2在基底细胞癌诊断中的敏感度高于CD34,特异度低于CD34,差异有统计学意义(P<0.05);两种检查方式在基底细胞癌诊断中的准确率比较,差异无统计学意义(P>0.05)。Bcl-2在毛发上皮瘤诊断中的敏感度高于CD34,特异度低于CD34,差异有统计学意义(P<0.05);两种检查方式的准确率比较,差异无统计学意义(P>0.05)。结论:Bcl-2在基底细胞癌和毛发上皮瘤中呈高表达,在疾病的鉴别诊断中具有重要意义。CD34基底细胞癌中不表达,在毛发上皮瘤呈低表达,对于疾病的诊断和鉴别无显著意义。

Tumor-derived DEFB1 induces immune tolerance by inhibiting maturation of dendritic cell and impairing CD8+T cell function in esophageal squamous cell carcinoma

Objective:CD8+T cells are the key effector cells in the anti-tumor immune response.The mechanism underlying the infiltration of CD8+T cells in esophageal squamous cell carcinoma(ESCC)has not been clearly elucidated.Methods:Fresh ESCC tissues were collected and grouped according to the infiltration density of CD8+T cells.After the transcriptome sequencing on these samples and the combined analyses with The Cancer Genome Atlas(TCGA)ESCC data,a secreted protein DEFB1 was selected to explore its potential role in the infiltration of CD8+T cells.Bioinformatics analyses,histological verification and in vitro experiments were then performed.Results:DEFB1 was highly expressed in ESCC,and the high expression of DEFB1 was an independent risk factor for overall survival.Since the up-regulation or down-regulation of DEFB1 did not affect the proliferation,migration and apoptosis of ESCC cells,we speculated that the oncogenic effect of DEFB1 was achieved by regulating microenvironmental characteristics.Bioinformatics analyses suggested that DEFB1 might play a major role in the inflammatory response and anti-tumor immune response,and correlate to the infiltration of immature dendritic cell(imDC)in ESCC.Histological analyses further confirmed that there were less CD8+T cells infiltrated,less CD83+mature DC(mDC)infiltrated and more CD1a+imDC infiltrated in those ESCC samples with high expression of DEFB1.After the treatment with recombinant DEFB1 protein,the maturation of DC was hindered significantly,followed by the impairment of the killing effects of T cells in both 2D and 3D culture in vitro.Conclusions:Tumor-derived DEFB1 can inhibit the maturation of DC and weaken the function of CD8+T cells,accounting for the immune tolerance in ESCC.The role of DEFB1 in ESCC deserves further exploration.

Predicting the Prognosis and Immunotherapeutic Response of Triple-Negative Breast Cancer by Constructing a Prognostic Model Based on CD8+T Cell-Related Immune Genes

Objective Triple-negative breast cancer(TNBC)poses a significant challenge for treatment efficacy.CD8+T cells,which are pivotal immune cells,can be effectively analyzed for differential gene expression across diverse cell populations owing to rapid advancements in sequencing technology.By leveraging these genes,our objective was to develop a prognostic model that accurately predicts the prognosis of patients with TNBC and their responsiveness to immunotherapy.Methods Sample information and clinical data of TNBC were sourced from The Cancer Genome Atlas and METABRIC databases.In the initial stage,we identified 67 differentially expressed genes associated with immune response in CD8+T cells.Subsequently,we narrowed our focus to three key genes,namely CXCL13,GBP2,and GZMB,which were used to construct a prognostic model.The accuracy of the model was assessed using the validation set data and receiver operating characteristic(ROC)curves.Furthermore,we employed various methods,including Kyoto Encyclopedia of Genes and Genomes(KEGG)pathway,immune infiltration,and correlation analyses with CD274(PD-L1)to explore the model's predictive efficacy in immunotherapeutic responses.Additionally,we investigated the potential underlying biological pathways that contribute to divergent treatment responses.Results We successfully developed a model capable of predicting the prognosis of patients with TNBC.The areas under the curve(AUC)values for the 1-,3-,and 5-year survival predictions were 0.618,0.652,and 0.826,respectively.Employing this risk model,we stratified the samples into high-and low-risk groups.Through KEGG enrichment analysis,we observed that the high-risk group predominantly exhibited enrichment in metabolism-related pathways such as drug and chlorophyll metabolism,whereas the low-risk group demonstrated significant enrichment in cytokine pathways.Furthermore,immune landscape analysis revealed noteworthy variations between(PD-L1)expression and risk scores,indicating that our model effectively predicted the response of patients to immune-based treatments.Conclusion Our study demonstrates the potential of CXCL13,GBP2,and GZMB as prognostic indicators of clinical outcomes and immunotherapy responses in patients with TNBC.These findings provide valuable insights and novel avenues for developing immunotherapeutic approaches targeting TNBC.

Donor-derived CD 19 CAR-T Cells versus Chemotherapy Plus Donor Lymphocyte Infusion for Treatment of Recurrent CD 19-positive B-ALL after Allogeneic Hematopoietic Stem Cell Transplantation

Objective:This study aimed to compare the efficacy of anti-CD19 chimeric antigen receptor T cells(CAR-T cells)versus chemotherapy plus donor lymphocyte infusion(chemo-DLI)for treating relapsed CD 19-positive B-cell acute lymphoblastic leukemia(B-ALL)after allogeneic hematopoietic stem cell transplantation(allo-HSCT).Methods:Clinical data of 43 patients with B-ALL who relapsed after allo-HSCT were retrospectively analyzed.Twenty-two patients were treated with CAR-T cells(CAR-T group),and 21 with chemotherapy plus DLI(chemo-DLI group).The complete remission(CR)and minimal residual disease(MRD)-negative CR rates,leukemia-free survival(LFS)rate,overall survival(OS)rate,and incidence of acute graft-versus-host disease(aGVHD),cytokine release syndrome(CRS)and immune effector cell-associated neurotoxicity syndrome(ICANS)were compared between the two groups.Results:The CR and MRD-negative CR rates in the CAR-T group(77.3%and 61.5%)were significantly higher than those in the chemo-DLI group(38.1%and 23.8%)(P=0.008 and P=0.003).The 1-and 2-year LFS rates in the CAR-T group were superior to those in the chemo-DLI group:54.5%and 50.0%vs.9.5%and 4.8%(P=0.0001 and P=0.00004).The 1-and 2-year OS rates in the CAR-T versus chemo-DLI group were 59.1%and 54.5%vs.19%and 9.5%(P=0.011 and P=0.003).Six patients(28.6%)with grade 2-4 aGVHD were identified in the chemo-DLI group.Two patients(9.1%)in the CAR-T group developed grade 1-2 aGVHD.Nineteen patients(86.4%)developed CRS in the CAR-T group,comprising grade 1-2 CRS in 13 patients(59.1%)and grade 3 CRS in 6 patients(27.3%).Two patients(9.1%)developed grade 1-2 ICANS.Conclusion:Donor-derived anti-CD19 CAR-T-cell therapy may be better,safer,and more effective than chemo-DLI for B-ALL patients who relapse after allo-HSCT.

Revolutionizing tumor immunotherapy:unleashing the power of progenitor exhausted T cells

In exploring persistent infections and malignancies, a distinctive subgroup of CD8^(+) T cells, progenitor exhausted CD8^(+) T(Tpex) cells, has been identified. These Tpex cells are notable for their remarkable self-renewal and rapid proliferation abilities. Recent strides in immunotherapy have demonstrated that Tpex cells expand and differentiate into responsive exhausted CD8^(+) T cells, thus underscoring their critical role in the immunotherapeutic retort. Clinical examinations have further clarified a robust positive correlation between the proportional abundance of Tpex cells and enhanced clinical prognosis. Tpex cells have found noteworthy applications in the formulation of inventive immunotherapeutic approaches against tumors. This review describes the functions of Tpex cells in the tumor milieu, particularly their potential utility in tumor immunotherapy. Precisely directing Tpex cells may be essential to achieving successful outcomes in immunotherapy against tumors.

THE EFFECT OF STEM CELL FACTOR, INTERLEUKIN-6 AND ERYTHROPOIETIN ON EXPANSION OF CD34^+ CELLS FROM HUMAN UMBILICAL CORD BLOOD

CD34+ cells from human umbilical cord blood were purified by Dynal beads M-450 CD34 immunoselection system and cultured in the presence of various cytokines alone or in combination, including stem cell factor (SCF), interleukin-6 (IL-6) and erythropoietin (EPO). The results revealed that: (D In methylcellulose culture, the plating efficiencies of purified cord blood CD34+ cells were much different when stimulated by various cytokines. IL-6 alone had the lowest colo-ny yield, while the combination of SCF, IL-6 and EPO had the highest yield. ② In the suspension culture, IL-6 alone or IL-6 + EPO had little expanding effect on cord blood CD34+ celis, the other cytokine combinations could expand cord blood CD34+ celis at different Ievels. Among them, the combination of SCF, IL-6 and EPO had the maximal expanding effect on cord blood CD34+ celis, the number of progenitor celis peaked at day 21, about 29-fold increase and nucleated celis increased approximately 3676-fold at day 28. The expanding effect of

CD34和S100共表达的ALK重排皮肤梭形细胞肿瘤2例及文献复习

目的报道2例具有独特形态学特征、CD34和S100共表达的间变性淋巴瘤激酶(ALK)重排皮肤梭形细胞肿瘤,以提高临床医师对该类软组织梭形细胞肿瘤的认识。方法收集2例外院会诊的病例,采用免疫组化EnVision二步法检测肿瘤中vimentin、ALK(D5F3)、BCL2、CD34及Ki-67的表达情况。1例使用荧光原位杂交(FISH)法断裂探针、1例通过二代测序(NGS)检测ALK基因重排。结果形态学上,肿瘤细胞由温和的梭形细胞或卵圆形细胞构成,呈束状或漩涡状排列,间质玻璃样变及黏液变性,可见较多开放的血管腔。该类肿瘤同时表达CD34和S100,存在ALK基因重排。结论2例CD34和S100共表达的ALK重排皮肤梭形细胞肿瘤具有独特的形态学,具有相同的免疫组化表达及分子特征,与NTRK重排梭形细胞肿瘤具有相似的临床病理学特征。

Effect of substrate temperature and oxygen plasma treatment on the properties of magnetron-sputtered CdS for solar cell applications

Cadmium sulfide(CdS)is an n-type semiconductor with excellent electrical conductivity that is widely used as an electron transport material(ETM)in solar cells.At present,numerous methods for preparing CdS thin films have emerged,among which magnetron sputtering(MS)is one of the most commonly used vacuum techniques.For this type of technique,the substrate temperature is one of the key deposition parameters that affects the interfacial properties between the target film and substrate,determining the specific growth habits of the films.Herein,the effect of substrate temperature on the microstructure and electrical properties of magnetron-sputtered CdS(MS-CdS)films was studied and applied for the first time in hydrothermally deposited antimony selenosulfide(Sb_(2)(S,Se)_(3))solar cells.Adjusting the substrate temperature not only results in the design of the flat and dense film with enhanced crystallinity but also leads to the formation of an energy level arrangement with a Sb_(2)(S,Se)_(3)layer that is more favorable for electron transfer.In addition,we developed an oxygen plasma treatment for CdS,reducing the parasitic absorption of the device and resulting in an increase in the short-circuit current density of the solar cell.This study demonstrates the feasibility of MS-CdS in the fabrication of hydrothermal Sb_(2)(S,Se)_(3)solar cells and provides interface optimization strategies to improve device performance.

高频彩超结合血清CD34、Tg、VEGF诊断甲状腺癌的临床价值

目的分析高频彩超结合血清细胞表面的唾液黏蛋白(CD)34、甲状腺球蛋白(Tg)、血管内皮生成因子(VEGF)诊断甲状腺癌的临床价值。方法选取2018年1月至2023年10月医院收治的50例疑似甲状腺癌患者,均采用高频彩超诊断,并检测Tg、VEGF、CD34表达。以手术病理结果为金标准,分为良性组与恶性组,分析对甲状腺癌的诊断价值。结果恶性组收缩期峰值流速(PSV)、阻力指数(RI)高于良性组,血流分级3级占比率高于良性组,纵横比>1、内部微钙化、后方衰减占比率均高于良性组(P<0.05)。恶性组血清Tg、VEGF、CD34表达水平均高于良性组(P<0.05)。绘制受试者工作特征曲线(ROC)后,高频彩超结合血清Tg、VEGF、CD34预测甲状腺癌的灵敏度(93.30%)、特异度(92.50%)均高于单一指标(P<0.05)。结论高频彩超结合血清CD34、Tg、VEGF表达诊断甲状腺癌的临床价值较高。

CD34和D2-40在原发性结肠腺癌中的表达及与伴淋巴结转移状态的关系

目的:探讨原发性结肠腺癌(colon adenocarcinoma,COAD)组织中血管和淋巴管标志物CD34(CD34 Molecule)和D2-40(又称Podoplanin)标记的癌胚抗原M2A的表达及其意义。方法:采用免疫组织化学Elivision TM plus法检测60例COAD组织和4例癌旁正常组织中CD34与D2-40标记的M2A蛋白表达,计数CD34阳性的微血管密度和D2-40阳性的微淋巴管密度,并分析其与COAD临床病理参数的关系。结果:在COAD组织中,CD34、D2-40阳性的微血管密度和微淋巴管密度高于癌旁正常组织(P<0.05)。COAD组织中的CD34微血管密度与病变部位有关,右半结肠癌患者中CD34微血管密度明显高于左半结肠癌患者(P<0.05);伴肠系膜淋巴结转移的COAD组织中CD34微血管密度与D2-40微淋巴管密度呈正相关(P<0.05)。结论:CD34和D2-40标记M2A蛋白在COAD组织中高表达,并且在伴肠系膜淋巴结转移状态下二者呈正相关,提示它们可能协同参与COAD淋巴结转移的发生。

Genetic modification of miR-34a enhances efficacy of transplanted human dental pulp stem cells after ischemic stroke

Human dental pulp stem cells(hDPSCs) promote recovery after ischemic stro ke;however,the therapeutic efficacy is limited by the poor survival of transplanted cells.For in vitro expe riments in the present study,we used oxygen-glucose deprivation/reoxygenation in hDPSCs to mimic cell damage induced by ischemia/reperfusion.We found that miRNA-34a-5p(miR-34a) was elevated under oxygen-glucose deprivation/reoxygenation conditions in hDPSCs.Inhibition of miR-34a facilitated the prolife ration and antioxidant capacity and reduced the apoptosis of hDPSCs.Moreove r,dual-luciferase reporter gene assay showed WNT1and SIRT1 as the targets of miR-34a.In miR-34a knockdown cell lines,WNT1 suppression reduced cell prolife ration,and SIRT1 suppression decreased the antioxidant capacity.Togethe r,these results indicated that miR-34a regulates cell prolife ration and antioxidant stress via targeting WNT1 and SIRT1,respectively.For in vivo expe riments,we injected genetically modified hDPSCs(anti34a-hDPSCs) into the brains of mice.We found that anti34a-hDPSCs significantly inhibited apoptosis,reduced cerebral edema and cerebral infarct volume,and improved motor function in mice.This study provides new insights into the molecular mechanism of the cell prolife ration and antioxidant capacity of hDPSCs,and suggests a potential gene that can be targeted to improve the survival rate and efficacy of transplanted hDPSCs in brain after ischemic stroke.

乳腺癌组织ER、P63、CD34表达水平及其与临床病理特征的关系分析

目的:研究乳腺癌组织雌激素受体(ER)、P63、CD34表达水平及其与临床病理特征的关系。方法:选取南通市通州区中医院2021年1月—2023年10月收治的72例乳腺癌患者开展研究。采集乳腺癌组织及癌旁正常组织,以免疫组织化学法检测ER、P63、CD34表达水平。对比不同乳腺组织ER、P63、CD34表达情况,分析上述三项蛋白表达情况与临床病理特征的关系。结果:乳腺癌组织ER及CD34阳性率均高于癌旁正常组织,而P63阳性率低于癌旁正常组织(均P<0.05)。病灶直径≥2 cm、TNM分期Ⅲ~Ⅳ期、淋巴结转移乳腺癌患者ER、CD34阳性率均高于病灶直径<2 cm、TNM分期Ⅰ~Ⅱ期、无淋巴结转移乳腺癌患者;而P63阳性率均低于病灶直径<2 cm、TNM分期Ⅰ~Ⅱ期、无淋巴结转移乳腺癌患者(均P<0.05)。结论:乳腺癌组织ER、CD34呈异常高表达,而P63呈异常低表达。上述三项蛋白表达水平与乳腺癌病灶直径、TNM分期及淋巴结转移密切相关。